BioSpace News Archive

ArcherDX, Inc., UCL and the Francis Crick Institute announced an extension to utilize personalized, liquid biopsy-based research assays for the duration of the TRACERx program, a major lung cancer research initiative funded by Cancer Research UK.

Syndax Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced that members of its management team will participate virtually in the BTIG Biotechnology Conference on Monday, August 10, 2020 at 12:00 p.m. ET.

More than 100,000 CytoSorb treatments delivered, tens of thousands of patients treated, and many lives saved

CASI Pharmaceuticals, Inc., a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, announced the Company will host a conference call reviewing the second quarter highlights at 4:30 p.m. ET on Monday, August 10th, 2020.

Schrödinger, whose physics-based software platform enables discovery of high-quality, novel molecules for therapeutics and materials, announced that it will host a conference call and webcast on Monday, August 10, 2020 at 8:30 a.m. ET to discuss second quarter 2020 financial results and provide a general business update.

IMV Inc. (“IMV” or the “Corporation”) (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines to fight against infectious diseases including COVID-19, announced today that it will hold a conference call and webcast on Wednesday, August 12, 2020 at 8:00 a.m. ET to discuss the company’s second quarter 2020 financial and operational results.

Humanigen, Inc. announced the appointment of Timothy E. Morris to the newly created role of Chief Operating Officer and Chief Financial Officer, effective immediately, reporting to Dr. Cameron Durrant, Chief Executive Officer.

Humanigen, Inc., announced that the Company will host an investor call and webcast to discuss the National Institute of Health’s selection of lenzilumab, the company’s proprietary Humaneered® anti-human granulocyte macrophage-colony stimulating factor monoclonal antibody drug candidate, as an agent to be evaluated in the NIAID-sponsored Big Effect Trial in hospitalized patients with COVID-19.

Company CEO Recognized for Launching US Outpost for Korea’s Samyang Pharmaceuticals and Innovative Leadership, Ability to Attract R&D Partnerships

Humanigen, Inc. , (OTCQB:HGEN) , announced today that the Company will host an investor call and webcast to discuss the National Institute of Health selection of lenzilumab